

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4775594

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	CONTINUUM LLC	11/06/2017
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	AMGEN INC.	
<b>Street Address:</b>	ONE AMGEN CENTER DRIVE	
<b>City:</b>	THOUSAND OAKS	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	91320	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	29554320
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(312)474-0448	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	312-474-6300	
<b>Email:</b>	docket@marshallip.com	
<b>Correspondent Name:</b>	MARSHALL, GERSTEIN & BORUN LLP (AMGEN)	
<b>Address Line 1:</b>	233 SOUTH WACKER DRIVE	
<b>Address Line 2:</b>	6300 WILLIS TOWER	
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60606-6357	
<b>ATTORNEY DOCKET NUMBER:</b>	32263/50326	
<b>NAME OF SUBMITTER:</b>	MICHAEL P. FURMANEK	
<b>SIGNATURE:</b>	/MICHEAL P. FURMANEK/	
<b>DATE SIGNED:</b>	01/13/2018	
<b>Total Attachments: 3</b>		
source=50396Assignment5#page1.tif		
source=50396Assignment5#page2.tif		
source=50396Assignment5#page3.tif		

## ASSIGNMENT

WHEREAS CONTINUUM LLC, having its registered office at 1220 Washington Street, West Newton, Massachusetts 02465, USA, (hereinafter referred to as ASSIGNOR), is the assignee of its entire right, title and interest in U.S. Patent Applications listed in the attached Schedule A ("Application"); and

Whereas AMGEN INC., a corporation organized under the laws of the State of Delaware and having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA wishes to acquire the entire right, title, and interest in all inventions disclosed in such Application;

Now, therefore, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns, transfers and sets over unto AMGEN INC., its successors and assigns (collectively "ASSIGNEE") ASSIGNOR'S entire right, title and interest in, to and under the Application, and any provisional application(s) from which Application is derived, and all priority rights to which the Application may be entitled, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all Letters Patent of the United States and of all other countries which may be granted for such inventions, or any of them, including divisional, continuation, continuation-in-part, substitute, reissue, and/or reexamination applications based on the above identified Application, all such inventions and all rights in such Application and Letters Patent to be held and enjoyed by ASSIGNEE for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, and any extensions thereof, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any foreign Patent Office authority to issue any such Letters Patent which may be granted on the Application to ASSIGNEE as assignee of the entire right, title and interest therein and thereto.

For ASSIGNOR and for ASSIGNOR'S legal representatives, ASSIGNOR covenants and agrees with ASSIGNEE that ASSIGNOR has not granted to any others any license to make, use or sell any of such inventions, that ASSIGNOR'S right, title and interest in such inventions has not been encumbered, that ASSIGNOR has good right and title to sell and assign the same, and that ASSIGNOR will not execute any instrument in conflict herewith.

For ASSIGNOR and for ASSIGNOR'S successors and legal representatives, ASSIGNOR further covenants and agrees with ASSIGNEE that upon request ASSIGNOR and ASSIGNOR'S successors and legal representatives will: (i) communicate to ASSIGNEE any facts known to ASSIGNOR or ASSIGNOR'S successors and legal representatives relating to such inventions or the history thereof; (ii) execute and deliver any application papers, assignments, or other instruments; and (iii) do all other acts which, in the opinion of counsel for ASSIGNEE, may be necessary or desirable to secure the grant of Letters Patent to ASSIGNEE or its nominees, in the United States and in all other countries where ASSIGNEE may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel

for ASSIGNEE and to vest and confirm in ASSIGNEE or its nominees the full and complete legal and equitable title to all such Letters Patent, without further consideration than that now paid at the expense of ASSIGNEE.

CONTINUUM LLC.

By: Tara Moran  
Name: Tara Moran  
Title: Global Legal Director  
Date: 11/6/17

DECLARATION OF ACCEPTANCE

On behalf of Assignee,

Stuart L. Watt  
Name

Vice President, Law and Intellectual Property Officer  
Title

hereby confirms Assignee's acceptance.

Nov. 6, 2017  
Date

Stuart L. Watt  
Signature

SCHEDULE A

Application Type (US)	Serial No.	Filing Date	Title	Amgen Ref. No.
Design Application	29/554,311	10 Feb 2016	On-Body Drug Injector for Drug Delivery	A-2042-US-DP
Design Application	29/554,320	10 Feb 2016	On-Body Drug Injector for Drug Delivery	A-2044-US-DP
Design Application	29/554,322	10 Feb 2016	On-Body Drug Injector for Drug Delivery	A-2045-US-DP
Design Application	29/556,037	26 Feb 2016	Graphical User Interface For Activating Drug Delivery and Communicating Drug Delivery Information	A-2046-US-DP
Provisional Application	62/412,365	25 Oct 2016	On-Body Injector	A-2107-0S-PSP
Provisional Application	62/467,602	06 Mar 2017	Drug Delivery Device with Activation Prevention Feature	A-2107-US-PSP2